Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy

Breast Cancer

Volumn 16, Issue 2, 2009, Pages 97-104

  Uematsu, Takayoshi ^a   Kasami, Masako ^a   Yuen, Sachiko ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Breast conserving therapy; MRI; PDG PET; Prognosis; Staging

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 65249085532     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-008-0065-9     Document Type: Article

References (30)

1. NIH Consensus Conference. Treatment of early-stage breast cancer. J Am Med Assoc. 1991;265:391-5.
2. FA Vicini TL Eberlein JL Connolly A Recht A Abner SJ Schnitt W Silen JR Harris 1991 The optimal extent of resection for patients with stages 1 or 2 breast cancer treated with conservative surgery and radiotherapy Ann Sur 214 200 4.
3. MC Smitt KW Nowels MJ Zdeblick S Jeffrey RW Carlson FE Stockdale DR Goffinet 1995 The importance of the lumpectomy surgical margin status in long term results of breast conservation Cancer 76 259 67.
4. I Gage SJ Schnitt AJ Nixon B Silver A Recht SL Troyan T Eberlein SM Love R Gelman JR Harris JL Connolly 1996 Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy Cancer 78 1921 8.
5. JL Connolly J Boyages AJ Nixon G Peiro B Silver A Recht JR Harris SJ Schnitt 1998 Predictors of breast recurrence after conservative surgery and radiation therapy for invasive breast cancer Mod Pathol 11 134 9.
6. Uematsu T, Yuen S, Kasami M, Uchida Y. Comparison of magnetic resonance imaging, multidetector row computed tomography, ultrasonography, and mammography for tumor extension of breast cancer. Breast Cancer Res Treat 2008; Epub ahead of print.
7. N Avril LP Adler 2007 F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging Radiol Clin North Am 45 645 57.
8. N Avril CA Rose M Schelling J Dose W Kuhn S Bense W Weber S Ziegler H Graeff M Schwaiger 2000 Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations J Clin Oncol 18 3495 502.
9. Schirrmeister H, Kuhn T, Guhlmann A, Santjohaser C, Horster T, Nuessle K, et al. Fluorine-18 2-deoxy-2 fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001;28:351-8.
10. A Rieber H Schirrmeister A Gabelmann K Nuessle S Reske R Kreienberg HJ Brambs T Kuhn 2002 Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk? Br J Radiol 75 789 98.
11. M Heinisch HJ Gallowitsch P Mikosch E Kresnik G Kumnig I Gomez P Lind HW Umschaden J Gasser EP Forsthuber 2003 Comparison of FDG-PET and dynamic contrast-enhanced MRI in the evaluation of suggestive breast lesions Breast 12 17 22.
12. Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer. 1998;82:2227-34.
13. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [18F]2-deoxy-2-fluoro-D- glucose-positron emission tomography. J Cancer Res Clin Oncol. 2004;130:273-8.
14. Cermik TF, Mavi A, Basu S, Alavi A. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging 2007;35(3):475-83.
15. American College of Radiology. Breast imaging reporting and data system (BI-RADS), 4th ed. American College of Radiology, Reston; 2003.
16. WA Berg L Gutierrez MS NessAiver WB Carter M Bhargavan RS Lewis OB Ioffe 2004 Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer Radiology 233 830 49.
17. T Uematsu M Sano K Homma N Sato 2002 Comparison between high-resolution helical CT and pathology in breast examination Acta Radiol 43 385 90.
18. RL Egan 1982 Multicentric breast carcinomas: clinical-radiographic- pathologic whole organ studies and 10-year survival Cancer 49 1123 30.
19. DRG Faverly JHCL Hendriks R Holland 2001 Breast carcinomas of limited extend Cancer 91 647 59.
20. D Vranjesevic C Schiepers DH Silverman A Quon J Villalpando M Dahlbom ME Phelps J Czernin 2003 Relationship between 18F-FDG uptake and breast density in women with normal breast tissue J Nucl Med 44 1238 42.
21. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, Maddahi J, Brunicardi FC, Phelps ME, Glaspy. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg. 1992;216:27-34.
22. F Crippa E Seregni R Agresti C Chiesa A Bogri D Decise V De Sanctis M Greco MG Daidone E Bombardieri 1998 Association between F-18 fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labeling index and p53 in primary breast cancer: a preliminary observation Eur J Nucl Med 25 1429 34.
23. N Avril M Menzel J Dose M Schelling W Weber F Janicke W Nathrath M Schwaiger 2001 Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis J Nucl Med 42 9 16.
24. RL Wahl BA Siegel E Coleman CG Gatsonis 2004 Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET study group J Clin Oncol 22 277 85.
25. PJ Lovrics V Chen G Coates SD Cornacchi CH Goldsmith C Law MN Levine K Sanders VR Tandan 2004 A prospective evaluation of positron emission tomography scanning sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer Ann Surg Oncol 11 846 53.
26. E Barranger D Grahek M Antoine F Montravers JN Talbot S Uzan 2004 Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer Ann Surg Oncol 10 622 7.
27. Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. Am J Roentgenol. 2004;183:479-86.
28. D Vranjesevic JE Filmont J Meta DH Silverman ME Phelps J Rao PE Valk J Czerin 2002 Whole-body (18) F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients J Nucl Med 43 325 9.
29. DH Monn J Maddahi DH Silverman JA Glaspy ME Phelps CK Hoh 1998 Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma J Nucl Med 39 431 5.
30. S Basu W Chen J Tchou A Mavi T Cermik B Czerniecki M Schnall A Alavi 2008 Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters Cancer 112 995 1000.